Soligenix

Soligenix EPS Growth

The EPS Growth of Soligenix (SNGX) as of Oct 17, 2026 is 66.59 %. In the previous year, EPS Growth was 65.17 % — a change of 2.18% (higher).

EPS Growth

66.59 %

YoY

2.18%

Last updated:

EPS Growth of Soligenix is 2025 66.59 % . EPS Growth of Soligenix was 2024 65.17 % . It decreases by 2.18% higher compared to the previous year.

The Soligenix EPS Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EPS Growth
Date
EPS Growth
Jan 1, 2018
59.02 USD
Jan 1, 2019
8.48 USD
Jan 1, 2020
-4,455.49 USD
Jan 1, 2021
50.33 USD
Jan 1, 2022
-8.96 USD
Jan 1, 2023
87.66 USD
Jan 1, 2024
65.17 USD
Jan 1, 2025
66.59 USD
The Soligenix EPS Growth history
YEAREPS GrowthYoY
66.59 %+2.18%
65.17 %-25.66%
87.66 %-1,078.10%
-8.96 %-117.81%
50.33 %-101.13%
-4,455.49 %-52,649.88%
8.48 %-85.63%
59.02 %-288.69%
-31.28 %-145.97%
68.03 %+669.13%
8.84 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Soligenix Stock analysis

What does Soligenix do? Soligenix Inc, trading under the ticker SNGX, is a biotechnology company based in Princeton, New Jersey. The company has an IPO date of April 4, 1994, and currently employs 13 people. Soligenix operates in the health care sector, specifically within biotechnology. The company focuses on developing and commercializing treatments for rare diseases. Its business segments include Specialized BioTherapeutics and Public Health Solutions. Under Specialized BioTherapeutics, Soligenix is developing SGX301, a photodynamic therapy using topical synthetic hypericin activated by visible light for cutaneous T-cell lymphoma (CTCL). The Public Health Solutions segment encompasses development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate targeting antibiotic-resistant and emerging infectious diseases. The company also references CTCL as an innate defense regulator technology, though this appears to be a misstatement as CTCL is a disease, not a technology. Soligenix's website is https://www.soligenix.com/. Soligenix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Soligenix stock

EPS Growth of Soligenix is 66.59 % in 2025.

On Eulerpool you can find the complete historical development of EPS Growth Soligenix since 2006 – with annual values, charts, and detailed analysis.

EPS growth measures the percentage change in earnings per share. It accounts for both profit changes and share count changes.

To evaluate EPS Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EPS Growth.

EPS Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EPS Growth's Soligenix historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Soligenix

All Key Metrics — Soligenix